Insider Selling: Phreesia, Inc. (NYSE:PHR) General Counsel Sells 4,585 Shares of Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 4,585 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $26.90, for a total transaction of $123,336.50. Following the transaction, the general counsel now directly owns 154,552 shares in the company, valued at approximately $4,157,448.80. This represents a 2.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Phreesia Stock Performance

Shares of NYSE PHR opened at $27.24 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $29.16. The stock has a 50-day moving average price of $23.42 and a two-hundred day moving average price of $22.77.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. The company had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm’s revenue was up 16.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.58) EPS. As a group, equities research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC boosted its holdings in shares of Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after acquiring an additional 1,395 shares in the last quarter. Lombard Odier Asset Management USA Corp bought a new position in Phreesia in the second quarter valued at about $202,000. Point72 DIFC Ltd bought a new position in Phreesia in the second quarter valued at about $209,000. XTX Topco Ltd bought a new stake in shares of Phreesia during the third quarter worth about $247,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Phreesia in the second quarter valued at approximately $301,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on PHR shares. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a report on Tuesday, December 10th. KeyCorp raised their price objective on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 8th. Citigroup upped their target price on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Needham & Company LLC restated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research report on Friday, January 10th. Finally, Robert W. Baird cut their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.